1. 560PImpact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial. (18th September 2017) Authors: Valerie, B.; Mollevi, C.; Chaput, N.; Gourgou, S.; Azria, D.; Seitz, J.F.; Bigot, L.; Juzyna, B.; Miran, I.; Gérard, J-P.; Laurent-Puig, P. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. (May 2017) Authors: Del Rio, M.; Mollevi, C.; Bibeau, F.; Vie, N.; Selves, J.; Emile, J.-F.; Roger, P.; Gongora, C.; Robert, J.; Tubiana-Mathieu, N.; Ychou, M.; Martineau, P. Journal: European journal of cancer Issue: Volume 76(2017) Page Start: 68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The anti-leukemic drug nilotinib inhibits metastatic properties of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1. (July 2016) Authors: Tosti, P.; Leroy, C.; Jeitany, M.; Simon, V.; Bonenfant, D.; Thouennon, L.; Elmessaoudi, S.; Mollevi, C.; Thierry, A.; Martineau, P.; Robert, B.; Sirvent, A.; Roche, S. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗